Catenibacterium

If you got a gut microbiome report back and this genus is flagged high, the useful question is not "how do I kill it." It's what else is going on. The research that names this organism keeps landing near smoking and metabolic dysfunction. Diet probably matters too, but the cleanest direct diet signal comes from humanized mice. That makes it a passenger more than a target.

That makes this a research marker, not a diagnostic one. There are no validated reference ranges for it, no clinical cutoff, and no evidence that acting on this number alone changes anyone's health. What it can do is give you a data point to track alongside the things that actually drive the biology.

What This Organism Actually Is

This is a group of closely related bacteria that live in the lower gut and can't survive in oxygen. Unlike most entries on a lab report, it's an organism rather than a substance your body makes. It belongs to the Erysipelotrichales order; some databases place it in the Coprobacillaceae family, while older papers often group the same lineage with Erysipelotrichaceae.

Labs identify it by detecting bacterial DNA in a stool sample. One common method is PCR, short for polymerase chain reaction, which copies selected stretches of DNA over and over until there is enough to identify which organisms are present.

Its job in the gut is fermentation. It breaks down glucose and can release acetic, lactic, butyric, and isobutyric acids. Those are small acids made when gut bacteria ferment food residues. Its genome also carries genes for handling carbohydrates. So it can help extract energy from food, but its abundance is not a simple score for diet quality.

One naming note, since people search for it: Catenibacterium mitsuokai is the best-described species in this genus. A genus-level test reports the group, not a single species.

Metabolic Syndrome and Obesity

The clearest human signal here is metabolic. In a study of Mexican children, this genus was significantly more abundant in kids who had obesity with metabolic syndrome than in comparison groups, and it appeared alongside disturbed blood lipid measures. The broader Erysipelotrichaceae lineage was also elevated, a pattern reported in obesity and lipid studies.

A separate case-control study of 46 young adults found higher relative abundance in women with polycystic ovary syndrome, a condition that often overlaps with insulin resistance. Both of these are cross-sectional snapshots. They show the organism in the same room as metabolic dysfunction; they don't show it holding the door open.

What this means for you: a high reading is a reason to look hard at your fasting insulin, triglycerides, and HbA1c, not a reason to chase the bacterium. If those markers are clean, the gut finding is interesting and not much more. If they're drifting, you've got a real target and this was the nudge.

Smoking

Smokers carry more of this genus than never-smokers, and the effect scales with how much they smoke. In 249 adults in Bangladesh, current smokers had about 1.9-fold higher mean relative abundance compared with people who had never smoked, and heavier tobacco exposure pushed the abundance higher still. The finding held after statistical correction for testing many organisms at once.

This is the tidiest step-by-step relationship in the literature on this organism: more smoking, more of the bug. It also tells you something about what the marker is tracking: not a discrete disease, but an exposure that reshapes the whole gut community.

Autism Spectrum Disorder

In one Lebanese pediatric study, children with autism spectrum disorder showed significantly higher relative abundance of this genus alongside lower levels of Bacteroidetes, one of the largest groups of bacteria in the human gut. Researchers have proposed that the shift could act on the gut-immune-brain connection by changing the small molecules gut bacteria release and the immune signals they set off.

That proposal has not been tested prospectively. Nothing about this finding makes the organism a screening tool, a diagnostic aid, or a treatment target for autism. It is a group-level association in a cross-sectional study, and a high reading in any individual carries no diagnostic meaning.

Why the Big Cohort Studies Don't Mention It

The evidence has a particular shape. Small cross-sectional studies find this genus near existing conditions. Large prospective cohorts that report microbiome predictors of future disease have not reported this genus as a major predictor.

A Finnish cohort followed 5,572 adults for a median of 15.8 years and identified four species that predicted incident type 2 diabetes. This genus was not among the reported predictors. A study of 6,419 adults over nearly 18 years found that each standard-deviation increase in butyrate-producing bacteria went with about 9% lower pneumonia risk; again, this organism was not one of the reported taxa. A 20-year hypertension study of 3,311 adults found no gut taxa held up once known confounders were accounted for. A 7,211-person mortality analysis pointed at Enterobacteriaceae, not this genus.

The one causal-style estimate that exists comes from genetic analysis rather than a stool measurement. Using inherited variants as a stand-in for abundance, researchers linked genetically predicted higher levels of this genus to modestly higher odds of diabetic nephropathy, which is kidney damage from diabetes, in a dataset with 4,111 cases and 308,539 controls. That method tests a genetic stand-in, not the number on your stool report, so it is not directly comparable to your result.

Reconciling the Two Pictures

So you have consistent cross-sectional associations with metabolic dysfunction on one hand, and null or absent signals from the biggest prospective cohorts on the other. These are not contradictory. They answer different questions.

Cross-sectional studies compare people who already have a condition against people who don't. They catch the organism where it accumulates. Prospective studies ask whether the organism predicts who develops the condition years later. Failing that second test means this is probably a marker of your current metabolic and lifestyle state, not an independent cause of future disease. Read it as a mirror, not a crystal ball.

Why One Reading Tells You Very Little

One practical point matters more than the rest. Individual bacterial genera in stool are unstable day to day. Daily quantitative profiling of healthy adults found that 78% of common gut genera varied more within the same person over time than between different people, with some genera shifting up to 100-fold. That day-to-day biological swing can be larger than the lab noise.

Low-abundance organisms are the least stable of all, which is exactly the category this one usually falls into. Your overall community fingerprint holds steady for months to years, so a single sample is fine for characterizing your broad microbiome. A single sample is not reliable for pinning down one genus.

If you want a usable number, sample on more than one day. Two or three collections spread over a week, or repeated testing at 3 to 6 months while you change something, gives you a trend. One reading is a weak signal. And if you are tracking whether an intervention worked, the trend is the only thing worth looking at.

When Your Result Can Mislead You

Beyond day-to-day swing, a few specific things can distort what you see:

• Stool consistency and transit time: how wet your stool is and how fast it moves through you shift the apparent composition without changing your underlying gut health. Bristol stool form on collection day influences the numbers.
• Recent antibiotics or H. pylori eradication: a 15-person pre/post study found this genus increased in stool and saliva two months after standard H. pylori eradication therapy. Any recent antibiotic course resets the community and makes a single reading unrepresentative.
• Acid-suppressing medication: in a randomized trial, a week of daily proton pump inhibitors drove more transfer of mouth bacteria into the gut than H2 blockers did. The trial did not report an effect on this genus specifically, but the drug can still shape what a gut profile shows.
• Lab method: DNA extraction technique, sequencing depth, and which reference database a lab uses all shift genus-level numbers. Results from two different labs are not directly comparable.

What To Do With an Unexpected Result

Treat a high reading as a prompt to check the things it travels with, not as a finding in itself. There is no antibiotic, probiotic, or protocol with evidence for lowering this specific organism, and no reason to think lowering it would help even if there were.

The productive move is to order the metabolic panel that the associations point to: fasting insulin, HbA1c, triglycerides, HDL, and hs-CRP. hs-CRP is a blood marker of low-grade inflammation. If several of those are drifting in the wrong direction at once, you have a genuine metabolic picture worth acting on, and the gut result was a useful early flag. If they're all clean, the gut finding stands alone and doesn't carry weight.

If you smoke, this result is one more data point in a very long list. If you have persistent gut symptoms, diarrhea, blood in stool, unintended weight loss, or fever, a harmless gut resident on a microbiome panel is not the explanation. That combination warrants a proper workup with a gastroenterologist, including a clinical stool pathogen panel and fecal calprotectin to check for real inflammation of the gut lining.

How This Differs From a Clinical Stool Panel

Standard clinical stool PCR panels, the ones used for acute diarrhea, look for pathogens: Campylobacter, Salmonella, Shigella, C. difficile. This genus is not on those panels because it does not cause disease, and there is no validated clinical sensitivity or specificity figure for detecting it.

That distinction matters because the general lesson from clinical stool PCR applies here too: detecting bacterial DNA is not the same as detecting a problem. In a retrospective analysis of 6,000 stool testing records, 356 samples were PCR-positive for bacterial pathogens and only 196 of those were confirmed by culture. In hospitalized patients, samples positive only for a strain of E. coli called EPEC often had documented non-infectious explanations for the diarrhea. High-sensitivity molecular detection finds things. Whether those things mean anything is a separate question, and for this organism the answer is still open.